Literature DB >> 11751995

ICA69(null) nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide.

Shawn Winer1, Igor Astsaturov, Roger Gaedigk, Denise Hammond-McKibben, Marc Pilon, Aihua Song, Violetta Kubiak, Wolfram Karges, Enrico Arpaia, Colin McKerlie, Peter Zucker, Bhagirath Singh, H-Michael Dosch.   

Abstract

ICA69 (islet cell Ag 69 kDa) is a diabetes-associated autoantigen with high expression levels in beta cells and brain. Its function is unknown, but knockout of its Caenorhabditis elegans homologue, ric-19, compromised neurotransmission. We disrupted the murine gene, ica-1, in 129-strain mice. These animals aged normally, but speed-congenic ICA69(null) nonobese diabetic (NOD) mice developed mid-life lethality, reminiscent of NOD-specific, late lethal seizures in glutamic acid decarboxylase 65-deficient mice. In contrast to wild-type and heterozygous animals, ICA69(null) NOD congenics fail to generate, even after immunization, cross-reactive T cells that recognize the dominant Tep69 epitope in ICA69, and its environmental mimicry Ag, the ABBOS epitope in BSA. This antigenic mimicry is thus driven by the endogenous self Ag, and not initiated by the environmental mimic. Insulitis, spontaneous, and adoptively transferred diabetes develop normally in ICA69(null) NOD congenics. Like glutamic acid decarboxylase 65, ICA69 is not an obligate autoantigen in diabetes. Unexpectedly, ICA69(null) NOD mice were resistant to cyclophosphamide (CY)-accelerated diabetes. Transplantation experiments with hemopoietic and islet tissue linked CY resistance to ICA69 deficiency in islets. CY-accelerated diabetes involves not only ablation of lymphoid cells, but ICA69-dependent drug toxicity in beta cells that boosts autoreactivity in the regenerating lymphoid system.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751995     DOI: 10.4049/jimmunol.168.1.475

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  IA-2 is not required for the development of diabetes in NOD mice.

Authors:  A Kubosaki; J Miura; Abner L Notkins
Journal:  Diabetologia       Date:  2003-11-12       Impact factor: 10.122

Review 2.  Mind the gap: analysis of marker-assisted breeding strategies for inbred mouse strains.

Authors:  Nicola J Armstrong; Thomas C Brodnicki; Terence P Speed
Journal:  Mamm Genome       Date:  2006-04-04       Impact factor: 2.957

3.  Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes.

Authors:  Kevan C Herold; Mark D Pescovitz; Paula McGee; Heidi Krause-Steinrauf; Lisa M Spain; Kasia Bourcier; Adam Asare; Zhugong Liu; John M Lachin; H Michael Dosch
Journal:  J Immunol       Date:  2011-07-20       Impact factor: 5.422

4.  Compromised central tolerance of ICA69 induces multiple organ autoimmunity.

Authors:  Yong Fan; Giulio Gualtierotti; Asako Tajima; Maria Grupillo; Antonina Coppola; Jing He; Suzanne Bertera; Gregory Owens; Massimo Pietropaolo; William A Rudert; Massimo Trucco
Journal:  J Autoimmun       Date:  2014-08-01       Impact factor: 7.094

Review 5.  Dissecting autoimmune diabetes through genetic manipulation of non-obese diabetic mice.

Authors:  Y Yang; P Santamaria
Journal:  Diabetologia       Date:  2003-10-28       Impact factor: 10.122

Review 6.  Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes.

Authors:  T P Di Lorenzo; M Peakman; B O Roep
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

Review 7.  T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes.

Authors:  Adam L Burrack; Tijana Martinov; Brian T Fife
Journal:  Front Endocrinol (Lausanne)       Date:  2017-12-05       Impact factor: 5.555

8.  PICK1 and ICA69 control insulin granule trafficking and their deficiencies lead to impaired glucose tolerance.

Authors:  Mian Cao; Zhuo Mao; Chuen Kam; Nan Xiao; Xiaoxing Cao; Chong Shen; Kenneth K Y Cheng; Aimin Xu; Kwong-Man Lee; Liwen Jiang; Jun Xia
Journal:  PLoS Biol       Date:  2013-04-23       Impact factor: 8.029

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.